This application will define mechanisms of rapamycin-mediated tumor onset delay or prevention and will dissect mTOR effects directly on the tumor versus immune cell effects. It addresses Provocative Question 5: defining mechanisms of action of drugs used for other purposes. We challenge the paradigm that mTOR inhibition reduces or prevents cancer by direct effects on tumors through mTOR growth and metabolic effects, and explore the potential for mTOR inhibitors to prevent cancer through mTOR-mediated immune effects. We hypothesize that mTOR inhibition with oral rapamycin delays or prevents cancer onset in part through immune mechanisms, and will test concepts in a well-defined carcinogen-induced skin cancer model in which T cells and IFN-? are important protective agents and in which mTOR inhibition prevents cancer. Mice will have tumor induced with dimethylbenz(a)-anthracene (DMBA) plus the promoter 12-O- tetradecanoylphorbol-13-acetate (TPA) and will be treated with oral rapamycin or control. Time to tumor onset, malignant change and tumor size and effects on tumor immune surveillance will be studied as will mTOR signaling in tumor versus other cells.
Aim 1 Test the hypothesis that T cells contribute to oral rapamycin- mediated cancer prevention.
Aim 2 Test the hypothesis that IFN-? contributes to oral rapamycin- mediated cancer prevention.
Aim 3 Test the hypothesis that rapamycin prevents cancer by direct effects on tumor cells. mTOR inhibition directly in tumors cell is not mutually exclusive with immune mechanisms. Relevance: Cancer is the number one killer in the US. Cure rates for advanced cancers have changed little in the past 50 years. Prevention is more cost effective and broadly applicable than treatments. We thus propose a novel, safe, broad spectrum approach to cancer prevention using rapamycin as a potential first-in-class agent.
This application will use a well-characterized carcinogen-induced mouse model for skin cancer to test whether immune effects of rapamycin contribute to its cancer prevention properties. This model mirrors important tumor signaling and host immune defense pathways involved in major human cancers.
| Liu, Yang; Pandeswara, Srilakshmi; Dao, Vinh et al. (2017) Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment. Cancer Res 77:520-531 |
| Hurez, V; Padrón, Á S; Svatek, R S et al. (2017) Considerations for successful cancer immunotherapy in aged hosts. Clin Exp Immunol 187:53-63 |
| Gupta, Harshita B; Clark, Curtis A; Yuan, Bin et al. (2016) Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduct Target Ther 1: |
| Dao, Vinh; Liu, Yang; Pandeswara, Srilakshmi et al. (2016) Immune-Stimulatory Effects of Rapamycin Are Mediated by Stimulation of Antitumor ?? T Cells. Cancer Res 76:5970-5982 |
| Clark, Curtis A; Gupta, Harshita B; Sareddy, Gangadhara et al. (2016) Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. Cancer Res 76:6964-6974 |
| Hurez, Vincent; Dao, Vinh; Liu, Aijie et al. (2015) Chronic mTOR inhibition in mice with rapamycin alters T, B, myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. Aging Cell 14:945-56 |
| Drerup, Justin M; Liu, Yang; Padron, Alvaro S et al. (2015) Immunotherapy for ovarian cancer. Curr Treat Options Oncol 16:317 |
| Dao, Vinh; Pandeswara, Srilakshmi; Liu, Yang et al. (2015) Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage. Cancer Prev Res (Phila) 8:400-9 |
| Hasty, Paul; Livi, Carolina B; Dodds, Sherry G et al. (2014) eRapa restores a normal life span in a FAP mouse model. Cancer Prev Res (Phila) 7:169-78 |
| Tomihara, Kei; Curiel, Tyler J; Zhang, Bin (2013) Optimization of immunotherapy in elderly cancer patients. Crit Rev Oncog 18:573-83 |
Showing the most recent 10 out of 11 publications
